HR Execs on the Move

TAU Systems

www.tausystems.com

 
TAU Systems is a deep-tech company developing the first compact particle accelerators and specialized X-ray free-electron lasers that combine the capabilities of large accelerators with a small footprint to provide easy and affordable beam-time access for any company. Led by premier experts in laser-driven particle accelerators, TAU is democratizing access for the progress of biotechnology, nuclear and more.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tausystems.com
  • 201 West 5th Street Suite 1100
    Austin, TX USA 78701
  • Phone: 512.900.1230

Executives

Name Title Contact Details

Similar Companies

Nanogen, Inc.

Nanogen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Spinal Dimensions

Spinal Dimensions is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forum Pharmaceuticals

FORUM Pharmaceuticals Inc. (“FORUM Pharmaceuticals” or “FORUM”) is dedicated to developing transformative medicines to restore the minds of people with serious brain disease, empowering them to preserve their identity, dignity and the essence of what makes us human. The Company`s diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM is privately owned and based in Waltham, Mass.

FarmaceuticalRx

Farmaceutical is a licensed medical marijuana business located in Pennsylvania and Ohio.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.